Three months into taking semaglutide, I found myself staring at a sandwich I’d made for lunch, feeling absolutely zero desire ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

Several new weight loss drugs are undergoing trials in the UK. These drugs will work similarly to those already available but ...

TAMPA, FL / ACCESS Newswire / July 29, 2025 / The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, ...

While Ozempic is effective at treating type 2 diabetes and supporting weight loss, it can also come with side effects.

Physicians detail five practical measures to optimize GLP-1 therapy and prevent muscle loss in patients undergoing weight reduction.

Over a fifth of people in the UK have tried to access a weight loss drug in the last year, according to a recent poll.Authors Liz Breen Professor ...

(Reuters) - Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival ...